Clinical Trials
2 trialsNCT04249622 2025-09-16
Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer
Mayo Clinic
Phase 2 Terminated
NCT01345175 2024-05-14
Rifaximin and Placebo in the Treatment of Bowel Dysfunction After Anterior Resection for Rectal Cancer
Memorial Sloan Kettering Cancer Center
Phase 3 Completed